AIVITA Doses First 10 Ovarian Cancer Patients with Cell-based Immunotherapy in Phase 2 Trial

AIVITA Doses First 10 Ovarian Cancer Patients with Cell-based Immunotherapy in Phase 2 Trial
The Phase 2 clinical trial evaluating AIVITA Biomedical’s cell-based immunotherapy for treating newly-diagnosed advanced ovarian cancer has dosed its first 10 patients. The study (NCT02033616) is looking to enroll 99 women at the Hoag Memorial Hospital Presbyterian in Newport Beach, California. Additional leading cancer centers may join the trial. Women with stage 3 or 4 epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who underwent surgery to remove the larger part of the tumor are eligible. Patients are required to be in good condition. In the study, patients are randomly assigned to the dendritic cell immunotherapy — called AVOVA-1 — or a monocyte placebo control. Monocytes are a cell type similar to dendritic cells. For every two patients receiving the active treatment, one will get a placebo. Dendritic cells are cells of the immune system whose job is to present certain proteins to T-cells, which have the capacity to kill tumor cells. AIVITA’s immunotherapy uses a patient’s own dendritic cells, which are boosted to fight the tumor. This is achieved by putting the dendritic cells together with the tumor cells in the lab, triggering the dendritic cells to present cancer-specific proteins at their surface. When re-injected into the patient, the dendritic cells will re-educate T-cells to react against the tumor cells. Researchers believe that the immunotherapy can kill the tumor-initiating cells — those responsible for the tumor growth, spreading, and relapse —
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *